[Comparison of benefits to non-dialysis CKD patients between darbepoetin alpha and epoetin beta pegol].

@article{Ito2015ComparisonOB,
  title={[Comparison of benefits to non-dialysis CKD patients between darbepoetin alpha and epoetin beta pegol].},
  author={Chiharu Ito and Tetsu Akimoto and Yoshiyuki Morishita and Hisashi Yamamoto and Manabu Ogura and Tomoyuki Yamazaki and Atsushi Miki and Sumiko Homma and Eiji Kusano and Yasushi Asano and Daisuke Nagata},
  journal={Nihon Jinzo Gakkai shi},
  year={2015},
  volume={57 7},
  pages={1233-40}
}
BACKGROUND Erythropoiesis-stimulating agents (ESAs) are the mainstay of treatment for renal anemia in chronic kidney disease (CKD) patients. However, the difference in hematopoietic effect between darbepoetin alfa (DA) and continuous erythropoiesis receptor activator (CERA) has remained unclear in non-dialysis CKD patients. Another purpose of this study was to analyze the red blood cells indices under treatment with these two ESAs in ESA-naïve CKD patients. METHODS This study was designed as… CONTINUE READING

Citations

Publications citing this paper.

Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy • 2018
View 20 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…